GlaxoSmithKline Plans Investment in Scotland - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

GlaxoSmithKline Plans Investment in Scotland


GlaxoSmithKline (GSK) plans to invest £25 million ($40.5 million) to expand its operations at its facility in Montrose, the United Kingdom, according to the Scottish Enterprise, Scotland's economic development agency. The investment is in addition to GSK’s earlier plan, announced in 2012, for investing £100 million ($162 million) in Montrose and the company’s other Scottish manufacturing site in Irvine.

With its most recent investment, GSK plans to bring production of the ingredients for four new pharmaceutical products to Montrose, according to the Scottish Enterprise. The investment will create an additional 25 new jobs for process technicians, engineers, and chemists, bringing the total GSK workforce in Scotland to more than 750. An additional fifty contractors will be employed during the construction phase. The Montrose site produces active ingredients for a number of drugs and the Irvine site produces antibiotics.

In 2012, GSK announced an initial investment of more than £100 million across its manufacturing sites in Montrose and Irvine, Scotland. This funding was targeted for manufacturing key materials for GSK’s portfolio of respiratory medicines as well as for producing aluminium adjuvants for vaccine manufacture. At Irvine, GSK's investment was targeted to increase production capacity for antibiotics.

Source: Scottish Enterprise

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here